Compounds > sb 216763
Page last updated: 2024-09-05

sb 216763 and pp242

sb 216763 has been researched along with pp242 in 1 studies

Compound Research Comparison

Studies
(sb 216763)		Trials
(sb 216763)		Recent Studies (post-2010)
(sb 216763)		Studies
(pp242)		Trials
(pp242)		Recent Studies (post-2010) (pp242)
3420225102098

Protein Interaction Comparison

ProteinTaxonomysb 216763 (IC50)pp242 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)1.8085
Tyrosine-protein kinase ABL1Homo sapiens (human)2.502
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)2.6263
Epidermal growth factor receptorHomo sapiens (human)4.4
Tyrosine-protein kinase HCKHomo sapiens (human)2.4678
Platelet-derived growth factor receptor betaHomo sapiens (human)2.6263
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)2.49
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.5011
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)1.9352
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)1.174
Serine/threonine-protein kinase mTORHomo sapiens (human)1.4284
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)1.3
Ephrin type-B receptor 4Homo sapiens (human)2.7122
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)1.8292
Receptor protein-tyrosine kinase Homo sapiens (human)2.6263
Rapamycin-insensitive companion of mTORHomo sapiens (human)0.08
Regulatory-associated protein of mTORHomo sapiens (human)0.008
Target of rapamycin complex 2 subunit MAPKAP1Homo sapiens (human)0.08
Target of rapamycin complex subunit LST8Homo sapiens (human)0.044
Phosphatidylinositol 4-kinase betaHomo sapiens (human)0.408

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gal, AA; Khuri, FR; Koo, J; Sun, SY; Yue, P1

Other Studies

1 other study(ies) available for sb 216763 and pp242

ArticleYear
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
    Cancer research, 2014, May-01, Volume: 74, Issue:9

    Topics: Animals; Antineoplastic Agents; Benzoxazoles; Cell Line, Tumor; Cyclin D1; F-Box Proteins; Female; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Indoles; Inhibitory Concentration 50; Maleimides; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Morpholines; Multiprotein Complexes; Naphthyridines; Protein Stability; Proteolysis; Purines; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014
chemdatabank.com